BACKGROUND: Somatostatin receptor scintigraphy (SRS) and octreotide therapy have both changed the management of gastroenteropancreatic endocrine tumours, but very few data are available on the use of SRS and octreotide to visualise and treat somatostatinomas. METHOD: The results of SRS and octreotide treatment in three somatostatinoma patients were examined. RESULTS: SRS was able to detect extensive hepatic involvement in patient 1, one hepatic and one pancreatic lesion in patient 2, and one hepatic lesion in patient 3. Octreotide therapy (0.5 mg/day subcutaneously) was effective in decreasing plasma levels of somatostatin in all three patients. Symptoms (diabetes and diarrhoea) were greatly improved in the two patients with "somatostatinoma syndrome". CONCLUSION: The study shows that somatostatinoma, like most other gastroenteropancreatic endocrine tumours, possesses functioning somatostatin receptors.
BACKGROUND: Somatostatin receptor scintigraphy (SRS) and octreotide therapy have both changed the management of gastroenteropancreatic endocrine tumours, but very few data are available on the use of SRS and octreotide to visualise and treat somatostatinomas. METHOD: The results of SRS and octreotide treatment in three somatostatinomapatients were examined. RESULTS:SRS was able to detect extensive hepatic involvement in patient 1, one hepatic and one pancreatic lesion in patient 2, and one hepatic lesion in patient 3. Octreotide therapy (0.5 mg/day subcutaneously) was effective in decreasing plasma levels of somatostatin in all three patients. Symptoms (diabetes and diarrhoea) were greatly improved in the two patients with "somatostatinoma syndrome". CONCLUSION: The study shows that somatostatinoma, like most other gastroenteropancreatic endocrine tumours, possesses functioning somatostatin receptors.
Authors: R Arnold; M E Trautmann; W Creutzfeldt; R Benning; M Benning; C Neuhaus; R Jürgensen; K Stein; H Schäfer; C Bruns; H J Dennler Journal: Gut Date: 1996-03 Impact factor: 23.059
Authors: V D Corleto; F Scopinaro; S Angeletti; A Materia; N Basso; E Polettini; B Annibale; O Schillaci; G D'Ambra; M Marignani; G Gualdi; C Bordi; E J Passaro; G Delle Fave Journal: World J Surg Date: 1996-02 Impact factor: 3.352
Authors: W H Bakker; R Albert; C Bruns; W A Breeman; L J Hofland; P Marbach; J Pless; D Pralet; B Stolz; J W Koper Journal: Life Sci Date: 1991 Impact factor: 5.037
Authors: M John; W Meyerhof; D Richter; B Waser; J C Schaer; H Scherübl; J Boese-Landgraf; P Neuhaus; C Ziske; K Mölling; E O Riecken; J C Reubi; B Wiedenmann Journal: Gut Date: 1996-01 Impact factor: 23.059
Authors: A Kubota; Y Yamada; S Kagimoto; A Shimatsu; M Imamura; K Tsuda; H Imura; S Seino; Y Seino Journal: J Clin Invest Date: 1994-03 Impact factor: 14.808
Authors: Roberto Baldelli; A Barnabei; L Rizza; A M Isidori; F Rota; P Di Giacinto; A Paoloni; F Torino; S M Corsello; A Lenzi; M Appetecchia Journal: Front Endocrinol (Lausanne) Date: 2014-02-07 Impact factor: 5.555